| Year |
Citation |
Score |
| 2021 |
Smith MR, Thomas S, Gormley M, Chowdhury S, Olmos D, Oudard SM, Feng FY, Rajpurohit Y, Urtishak KA, Ricci DS, Rooney OB, Lopez-Gitlitz A, Yu MK, Wyatt AW, Li M, et al. Blood Biomarker Landscape in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34112710 DOI: 10.1158/1078-0432.CCR-21-0358 |
0.328 |
|
| 2021 |
Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, et al. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. Jama Oncology. PMID 34081076 DOI: 10.1001/jamaoncol.2021.1463 |
0.33 |
|
| 2020 |
Uemura H, Satoh T, Tsumura H, Arai G, Imanaka K, Shibayama K, Fujii K, Rooney B, Lopez-Gitlitz A, Espina B, Perez-Ruixo C, Small EJ, Smith M. Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study. Prostate International. 8: 190-197. PMID 33425798 DOI: 10.1016/j.prnil.2020.05.002 |
0.362 |
|
| 2020 |
Uemura H, Matsushima H, Kobayashi K, Mizusawa H, Nishimatsu H, Fizazi K, Smith M, Shore N, Tammela T, Tabata KI, Matsubara N, Iinuma M, Uemura H, Oya M, Momma T, et al. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial. International Journal of Clinical Oncology. PMID 33226524 DOI: 10.1007/s10147-020-01824-5 |
0.321 |
|
| 2020 |
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, et al. Apalutamide and Overall Survival in Prostate Cancer. European Urology. PMID 32907777 DOI: 10.1016/J.Eururo.2020.08.011 |
0.346 |
|
| 2020 |
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR, et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. The New England Journal of Medicine. 383: 1040-1049. PMID 32905676 DOI: 10.1056/NEJMoa2001342 |
0.311 |
|
| 2020 |
Perez-Ruixo C, Ackaert O, Ouellet D, Chien C, Uemura H, Olmos D, Mainwaring P, Lee JY, Yu MK, Perez Ruixo JJ, Smith MR, Small EJ. Efficacy and safety exposure-response relationships of apalutamide in patients with non-metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32561663 DOI: 10.1158/1078-0432.CCR-20-1041 |
0.31 |
|
| 2020 |
Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, ... Smith M, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology. PMID 32001144 DOI: 10.1016/J.Eururo.2020.01.012 |
0.35 |
|
| 2020 |
Smith MR, Agarwal N, Todenhöfer T, Trepiakas R, Lee J, Lithio A, Chapman S, Nacerddine K, Sweeney C. CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 38: TPS5591-TPS5591. DOI: 10.1200/jco.2020.38.15_suppl.tps5591 |
0.311 |
|
| 2020 |
Saad F, Graff JN, Hadaschik BA, Oudard S, Mainwaring PN, Bhaumik A, Gormley M, Londhe A, Thomas S, Lopez-Gitlitz A, Mundle S, Davicioni E, Small EJ, Smith MR, Feng FY. Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN. Journal of Clinical Oncology. 38: 5521-5521. DOI: 10.1200/Jco.2020.38.15_Suppl.5521 |
0.347 |
|
| 2020 |
Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, ... ... Smith M, et al. Accelerating precision medicine in metastatic prostate cancer Nature Cancer. 1: 1041-1053. DOI: 10.1038/s43018-020-00141-0 |
0.352 |
|
| 2019 |
Smith MR, Mehra M, Nair S, Lawson J, Small EJ. Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer. PMID 31980408 DOI: 10.1016/j.clgc.2019.10.030 |
0.322 |
|
| 2019 |
Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, et al. Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31511295 DOI: 10.1158/1078-0432.Ccr-19-1050 |
0.338 |
|
| 2019 |
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. The New England Journal of Medicine. PMID 30763142 DOI: 10.1056/NEJMoa1815671 |
0.353 |
|
| 2019 |
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology. PMID 30738780 DOI: 10.1016/S1470-2045(18)30860-X |
0.351 |
|
| 2019 |
Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Espina BM, Shu Y, Rackoff WR, Rooney OB, ... Smith MR, et al. Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology. 37: 144-144. DOI: 10.1200/Jco.2019.37.7_Suppl.144 |
0.31 |
|
| 2019 |
Pollock YG, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Olmos D, Mainwaring PN, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney OB, Lopez-Gitlitz A, Mundle S, et al. Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). Journal of Clinical Oncology. 37: 5025-5025. DOI: 10.1200/Jco.2019.37.15_Suppl.5025 |
0.308 |
|
| 2019 |
Graff JN, Smith MR, Saad F, Hadaschik BA, Uemura H, Lee JY, Mainwaring PN, Olmos D, Oudard S, Londhe A, Bhaumik A, Rooney OB, Lopez-Gitlitz A, Small EJ. Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN Journal of Clinical Oncology. 37: 5024-5024. DOI: 10.1200/Jco.2019.37.15_Suppl.5024 |
0.314 |
|
| 2019 |
Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Londhe A, Bhaumik A, Cheng S, Rooney OB, Smith MR, et al. Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM). Journal of Clinical Oncology. 37: 5023-5023. DOI: 10.1200/Jco.2019.37.15_Suppl.5023 |
0.321 |
|
| 2019 |
Hadaschik BA, Saad F, Graff JN, Olmos D, Oudard S, Mainwaring PN, Uemura H, Lee JY, Lopez-Gitlitz A, Bhaumik A, Londhe A, Cheng S, Todd MB, Small EJ, Smith MR. Mp34-19 Efficacy And Safety Of Apalutamide (Apa) In Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc) Patients (Pts) With Or Without Prior Radical Prostatectomy (Rp) And/Or External Radiotherapy (Xrt): Post Hoc Analysis Of Spartan The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555933.20995.42 |
0.321 |
|
| 2019 |
Graff JN, Saad F, Hadaschik BA, Mainwaring PN, Uemura H, Chowdhury S, Oudard S, Olmos D, Lee JY, Lopez-Gitlitz A, Bhaumik A, Londhe A, Cheng S, Todd MB, Smith MR, et al. Mp34-20 Metastasis-Free Survival (Mfs) In Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc) Patients (Pts) With Prostate-Specific Antigen (Psa) Decline To < 0.2 Ng/Ml Following Apalutamide (Apa) Treatment: Post Hoc Results From The Phase 3 Spartan Study The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555927.90500.B0 |
0.348 |
|
| 2019 |
Chi K, Rathkopf D, Attard G, Smith M, Efstathiou E, Olmos D, Small E, Lee J, Sieber P, Dunshee C, Ricci D, Simon J, Zhao X, Kothari N, Cheng S, et al. A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641) Annals of Oncology. 30: v354. DOI: 10.1093/annonc/mdz248.054 |
0.321 |
|
| 2018 |
Smith MR, Perez-Ruixo C, Ackaert O, Ouellet D, Chien C, Uemura H, Olmos D, Mainwaring PN, Lee JY, Yu MK, Perez-Ruixo JJ, Small EJ. Relationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii278. PMID 32136638 DOI: 10.1093/annonc/mdy284.015 |
0.302 |
|
| 2018 |
Sonpavde GP, Pond GR, Fizazi K, de Bono JS, Basch EM, Scher HI, Smith MR. Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. European Urology Oncology. PMID 31412002 DOI: 10.1016/j.euo.2018.11.006 |
0.307 |
|
| 2018 |
Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology. PMID 30213449 DOI: 10.1016/S1470-2045(18)30456-X |
0.322 |
|
| 2018 |
Fizazi K, Smith MR, Tombal B. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. Clinical Genitourinary Cancer. PMID 30197098 DOI: 10.1016/j.clgc.2018.07.017 |
0.376 |
|
| 2018 |
Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS. Managing Nonmetastatic Castration-resistant Prostate Cancer. European Urology. PMID 30119985 DOI: 10.1016/j.eururo.2018.07.035 |
0.347 |
|
| 2018 |
Smith MR. Progress in Nonmetastatic Prostate Cancer. The New England Journal of Medicine. 378: 2531-2532. PMID 29949488 DOI: 10.1056/NEJMe1805733 |
0.353 |
|
| 2018 |
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. The New England Journal of Medicine. PMID 29420164 DOI: 10.1056/Nejmoa1715546 |
0.344 |
|
| 2018 |
Miyamoto DT, Lee RJ, Kalinich M, LiCausi J, Zheng Y, Chen T, Milner JD, Emmons E, Ho U, Broderick K, Silva E, Javaid S, Kwan TT, Hong X, Dahl DM, ... ... Smith MR, et al. An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer. Cancer Discovery. PMID 29301747 DOI: 10.1158/2159-8290.Cd-16-1406 |
0.363 |
|
| 2018 |
Smith MR, Saad F, Hussain M, Sternberg CN, Fizazi K, Yamada KS, Kappeler C, Kuss I, Tombal BF. ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps383 |
0.318 |
|
| 2018 |
Small EJ, Saad F, Zheng Y, Pan F, Mehra M, Lawson J, Hadaschik BA, Uemura H, Lee JY, Mainwaring PN, Smith MR. Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burden. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E17010 |
0.349 |
|
| 2018 |
Small EJ, Saad F, Rathkopf DE, Hadaschik BA, Chowdhury S, Yu MK, Lopez-Gitlitz A, Rooney OB, Shu Y, Darif M, Smith MR. Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial. Journal of Clinical Oncology. 36: 5034-5034. DOI: 10.1200/Jco.2018.36.15_Suppl.5034 |
0.35 |
|
| 2018 |
Mainwaring P, Small E, Uemura H, Lee J, Pang S, Marx G, Kwon T, Satoh T, Bhaumik A, Cheng S, Londhe A, Lopez-Gitlitz A, Smith M. Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation Annals of Oncology. 29: ix68. DOI: 10.1093/ANNONC/MDY434.001 |
0.306 |
|
| 2018 |
Saad F, Small E, Hadaschik B, Graff J, Mainwaring P, McQuarrie K, Li S, Lawson J, Lopez-Gitlitz A, Smith M. Patient (pt) reported outcomes (PROs) in SPARTAN, a phase 3, double-blind, randomized study of apalutamide (APA) plus androgen deprivation therapy (ADT) vs placebo (PBO) plus ADT in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) European Urology Supplements. 17: e1070-e1071. DOI: 10.1016/S1569-9056(18)31578-1 |
0.342 |
|
| 2018 |
Small EJ, Lee JY, Lopez-Gitlitz A, Saad F, Rooney B, Hadaschik BA, Uemura H, Shu Y, Yu M, Smith MR. Pd10-11 Prostate-Specific Antigen (Psa) Outcomes In Patients (Pts) With Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc) Treated With Apalutamide (Apa): Results From Phase 3 Spartan Study The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.621 |
0.327 |
|
| 2018 |
Saad F, Mehra M, Small EJ, Lawson J, Dasgupta A, Hadaschik BA, Uemura H, Smith MR. Pd10-04 A Population-Based Study Of The Association Of Prostate-Specific Antigen Doubling Time (Psadt) With Metastasis-Free Survival (Mfs) And Overall Survival (Os) In Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc) Patients (Pts) The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.614 |
0.311 |
|
| 2018 |
Small EJ, Saad F, Hadaschik BA, Graff JN, Mainwaring PN, McQuarrie K, Li S, Lawson J, Lopez-Gitlitz A, Smith MR. Mp52-20 Patient Reported Outcomes (Pros) In Spartan, A Phase 3, Double-Blind, Randomized Study Of Apalutamide (Apa) Plus Androgen Deprivation Therapy (Adt) Vs Placebo Plus Adt In Men With Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc) The Journal of Urology. 17. DOI: 10.1016/J.Juro.2018.02.1671 |
0.346 |
|
| 2017 |
Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon A, Fizazi K, Fleisher M, de Bono JS, Scher HI. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017752998. PMID 29272162 DOI: 10.1200/Jco.2017.75.2998 |
0.311 |
|
| 2017 |
Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baron B, Krivoshik A, Hirmand M, Smith MR. Long-term Anti-tumor Activity and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 3-year, Open-label, Follow-up Results. The Journal of Urology. PMID 28867562 DOI: 10.1016/j.juro.2017.08.103 |
0.316 |
|
| 2017 |
Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, ... Smith M, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology. PMID 28655541 DOI: 10.1016/J.Eururo.2017.06.002 |
0.357 |
|
| 2017 |
Smith MR, Saad F, Rathkopf DE, Mulders PF, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. European Urology. PMID 28314611 DOI: 10.1016/J.Eururo.2017.03.007 |
0.335 |
|
| 2017 |
Smith MR, Saad F, Hussain M, Sternberg CN, Fizazi K, Crawford ED, Yamada KS, Kappeler C, Kuss I, Tombal BF. ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC). Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps5092 |
0.323 |
|
| 2017 |
Tombal B, Saad F, Hussain M, Sternberg CN, Fizazi K, Crawford ED, Yamada K, Kappeler C, Kuss I, Smith MR. 838TiPARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx370.055 |
0.316 |
|
| 2017 |
Smith M, Saad F, Hussain M, Sternberg C, Fizazi K, Crawford D, Yamada K, Kappeler C, Kuss I, Tombal B. A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS) European Urology Supplements. 16. DOI: 10.1016/S1569-9056(17)30272-5 |
0.315 |
|
| 2016 |
Fu AZ, Tsai HT, Haque R, Ulcickas Yood M, Cassidy-Bushrow AE, Van Den Eeden SK, Keating NL, Smith MR, Zhou Y, Aaronson DS, Potosky AL. Mortality and Androgen-Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. The Journal of Urology. PMID 28007467 DOI: 10.1016/j.juro.2016.12.086 |
0.351 |
|
| 2016 |
de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PF, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. European Urology. PMID 27402060 DOI: 10.1016/J.Eururo.2016.06.033 |
0.324 |
|
| 2016 |
Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Vuillemin AT, Feyerabend S, et al. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27400947 DOI: 10.1200/Jco.2015.65.5597 |
0.325 |
|
| 2016 |
Watkins JM, Mitchell DL, Russo JK, Mott SL, Tracy CR, Smith MC, Buatti JM. Gleason Score ≤ 6 Prostate Cancer at Radical Prostatectomy: Does a High-Risk Setting Truly Exist? A Recursive Partitioning Analysis. Clinical Genitourinary Cancer. PMID 27338519 DOI: 10.1016/j.clgc.2016.05.016 |
0.339 |
|
| 2016 |
Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, De Porre P, Vermeulen A, Poggesi I, Nandy P. Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Pharmacokinetics. PMID 27324190 DOI: 10.1007/S40262-016-0425-0 |
0.338 |
|
| 2016 |
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27141017 DOI: 10.1093/Annonc/Mdw180 |
0.354 |
|
| 2016 |
Fu AZ, Tsai HT, Haque R, Ulcickas Yood M, Van Den Eeden SK, Cassidy-Bushrow AE, Zhou Y, Keating NL, Smith MR, Aaronson DS, Potosky AL. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer. World Journal of Urology. PMID 27084777 DOI: 10.1007/s00345-016-1823-5 |
0.327 |
|
| 2016 |
Voog JC, Smith MR, Efstathiou JA. Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. Jama. 315: 1054-5. PMID 26954419 DOI: 10.1001/Jama.2015.17567 |
0.319 |
|
| 2016 |
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, ... Smith MR, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26903579 DOI: 10.1200/Jco.2015.64.2702 |
0.337 |
|
| 2016 |
Fizazi K, Shore ND, Tammela TLJ, Sarapohja T, Vuorela A, Kuss I, Snapir A, Smith MR. ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 34: TPS5094-TPS5094. DOI: 10.1200/JCO.2016.34.15_SUPPL.TPS5094 |
0.319 |
|
| 2016 |
Suzuki K, Kuss I, Smith MR, Fizazi K. ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer Annals of Oncology. 27: vii106. DOI: 10.1093/annonc/mdw524.007 |
0.319 |
|
| 2016 |
Freedland S, Aronson W, Howard L, Smith J, Smith M, Stout J, Allen J, George D, Armstrong A, Inman B, Lin P. MP04-06 A PROSPECTIVE RANDOMIZED TRIAL OF DIETARY CARBOHYDRATE RESTRICTION FOR MEN INITIATING ANDROGEN DEPRIVATION THERAPY: CARBOHYDRATE AND PROSTATE STUDY I (CAPS1) Journal of Urology. 195. DOI: 10.1016/J.JURO.2016.02.1941 |
0.313 |
|
| 2015 |
Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, et al. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. European Urology. PMID 26362090 DOI: 10.1016/J.Eururo.2015.08.027 |
0.322 |
|
| 2015 |
Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, Kheoh T, Griffin TW, Molina A, Ryan CJ. Efficacy and Safety of Abiraterone Acetate in Elderly (≥75 Years) Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer. The Journal of Urology. PMID 26151676 DOI: 10.1016/j.juro.2015.07.004 |
0.339 |
|
| 2015 |
Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, et al. Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. European Urology. PMID 25985882 DOI: 10.1016/J.Eururo.2015.04.032 |
0.322 |
|
| 2015 |
Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, Vermeulen A, Poggesi I, Nandy P. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3170-7. PMID 25829400 DOI: 10.1158/1078-0432.Ccr-14-1549 |
0.307 |
|
| 2015 |
Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung, Baron B, Hirmand M, Smith MR, et al. Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. European Urology. PMID 25687533 DOI: 10.1016/j.eururo.2015.01.027 |
0.373 |
|
| 2015 |
Tsai HT, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Smith MR, Potosky AL. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. The Journal of Urology. 193: 1956-62. PMID 25524243 DOI: 10.1016/j.juro.2014.12.027 |
0.32 |
|
| 2015 |
Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, Shore N, Oudard S, Karsh L, Carducci M, Damião R, Wang H, Ying W, Goessl C. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. European Urology. 68: 42-50. PMID 25449207 DOI: 10.1016/j.eururo.2014.10.001 |
0.331 |
|
| 2015 |
Scher HI, Morris MJ, Stadler WM, Higano CS, Halabi S, Smith MR, Basch EM, Fizazi K, Ryan CJ, Antonarakis ES, Corn PG, Liu G, De Bono JS, Schwartz LH, Beer TM, et al. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 33: 5000-5000. DOI: 10.1200/JCO.2015.33.15_SUPPL.5000 |
0.351 |
|
| 2015 |
Saad F, Bono JSD, Smith MR, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, Porre PD, Kheoh T, Li J, Todd MB, Griffin TW, Ryan CJ. 668 Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302 European Urology Supplements. 14. DOI: 10.1016/S1569-9056(15)60661-3 |
0.341 |
|
| 2015 |
Mulders PFA, Smith MR, Fizazi K, Saad F, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin M, Higano CS, Souza PD, Bono JSD, et al. 556 Abiraterone acetate improves overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Impact of crossover and baseline prognostic factors in the COU-AA-302 final analysis European Urology Supplements. 14. DOI: 10.1016/S1569-9056(15)60549-8 |
0.302 |
|
| 2015 |
Shore ND, Antonarakis ES, Ryan CJ, Berry WR, Liu G, Higano C, Chow Maneval E, Bandekar R, de Boer CJ, Todd MB, Yu MK, Rathkopf DE, Smith MR. MP87-16 NOVEL ANTIANDROGEN ARN-509 IN HIGH-RISK NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER Journal of Urology. 193. DOI: 10.1016/J.JURO.2015.02.1961 |
0.322 |
|
| 2015 |
Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options European Urology. DOI: 10.1016/j.eururo.2015.06.039 |
0.345 |
|
| 2014 |
Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3391-9. PMID 25225437 DOI: 10.1200/JCO.2013.54.5954 |
0.302 |
|
| 2014 |
Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, Wang SL, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith MR, Michaelson MD. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clinical Genitourinary Cancer. 12: 317-24. PMID 24806399 DOI: 10.1016/j.clgc.2014.03.005 |
0.325 |
|
| 2014 |
Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). European Urology. 66: 815-25. PMID 24647231 DOI: 10.1016/J.Eururo.2014.02.056 |
0.34 |
|
| 2014 |
Potosky AL, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Jiang M, Tsai HT, Luta G, Keating NL, Smith MR, Van Den Eeden SK. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1324-30. PMID 24638009 DOI: 10.1200/JCO.2013.52.5782 |
0.33 |
|
| 2014 |
Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1143-50. PMID 24590644 DOI: 10.1200/Jco.2013.51.6500 |
0.367 |
|
| 2014 |
Sonpavde G, Pond GR, Armstrong AJ, Galsky MD, Leopold L, Wood BA, Wang SL, Paolini J, Chen I, Chow-Maneval E, Mooney DJ, Lechuga M, Smith MR, Michaelson MD. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. Bju International. 114: E25-31. PMID 24298897 DOI: 10.1111/bju.12589 |
0.36 |
|
| 2014 |
Saylor PJ, Smith MR, O'Malley AJ, Keating NL. Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer. European Urology. 65: 642-9. PMID 23428068 DOI: 10.1016/j.eururo.2013.02.003 |
0.316 |
|
| 2014 |
Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Smith MR. Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients. Journal of Clinical Oncology. 32: 62-62. DOI: 10.1200/JCO.2014.32.4_SUPPL.62 |
0.33 |
|
| 2014 |
Xu S, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, Vermeulen A, Poggesi I, Nandy P. Relationship between abiraterone exposure, prostate-specific antigen (PSA) kinetics, and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) . Journal of Clinical Oncology. 32: 39-39. DOI: 10.1200/Jco.2014.32.4_Suppl.39 |
0.314 |
|
| 2014 |
Smith MR, Liu G, Shreeve SM, Matheny S, Sosa A, Kheoh TS, Yu MK, Small EJ. A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) versus ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC): The SPARTAN trial. Journal of Clinical Oncology. 32: TPS5100-TPS5100. DOI: 10.1200/JCO.2014.32.15_SUPPL.TPS5100 |
0.333 |
|
| 2014 |
Klotz L, Smith MR, Coleman RE, Pittman KB, Milecki P, Wei R, Balakumaran A, Fizazi K. Symptomatic skeletal events (SSE) in patients with advanced prostate cancer: Results from a phase III trial of denosumab for the prevention of skeletal-related events. Journal of Clinical Oncology. 32: 5075-5075. DOI: 10.1200/JCO.2014.32.15_SUPPL.5075 |
0.3 |
|
| 2014 |
Borre M, Smith M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Baron B, Hirmand M, et al. P060 Enzalutamide monotherapy in patients with hormone-naive prostate cancer: 1-year extended follow-up of a Phase 2 study European Urology Supplements. 13: 131. DOI: 10.1016/S1569-9056(14)61283-5 |
0.322 |
|
| 2014 |
Schrijvers D, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf D, Saad F, Scher HI, Oudard S, Bellmunt J, Taplin M, Davis ID, Protheroe A, et al. 861 Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 European Urology Supplements. 13. DOI: 10.1016/S1569-9056(14)60848-4 |
0.335 |
|
| 2014 |
Tsai H, Keating NL, Ulcickas Yood M, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Smith MR, Potosky AL. Risk of Diabetes Among Patients Exposed to Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer Annals of Epidemiology. 24: 682. DOI: 10.1016/J.ANNEPIDEM.2014.06.009 |
0.312 |
|
| 2013 |
Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, Martin AG, Kim HE, Nabid A, Lawton CA. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. Prostate Cancer and Prostatic Diseases. 16: 382-6. PMID 24080992 DOI: 10.1038/pcan.2013.35 |
0.308 |
|
| 2013 |
Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. The Lancet. Oncology. 14: 1193-9. PMID 24075621 DOI: 10.1016/S1470-2045(13)70424-8 |
0.327 |
|
| 2013 |
Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3800-6. PMID 24043751 DOI: 10.1200/Jco.2012.44.6716 |
0.35 |
|
| 2013 |
Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3088-94. PMID 23553848 DOI: 10.1158/1078-0432.Ccr-13-0319 |
0.301 |
|
| 2013 |
Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. The Journal of Urology. 189: S45-50. PMID 23234631 DOI: 10.1016/j.juro.2012.11.016 |
0.302 |
|
| 2013 |
Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? European Urology. 64: 159-66. PMID 22537796 DOI: 10.1016/j.eururo.2012.04.035 |
0.313 |
|
| 2013 |
Ryan CJ, Londhe A, Molina A, Smith MR, Bono JSD, Mulders P, Rathkopf DE, Saad F, Logothetis C, Fizazi K, Scher HI, Small EJ, Matheny S, Kheoh TS, Griffin TW. Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. Journal of Clinical Oncology. 31: 5010-5010. DOI: 10.1200/Jco.2013.31.15_Suppl.5010 |
0.303 |
|
| 2013 |
Smith MR, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Baskin-Bey E, Perabo F, Phung D, Tombal B. Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC). Journal of Clinical Oncology. 31: 5001-5001. DOI: 10.1200/JCO.2013.31.15_SUPPL.5001 |
0.309 |
|
| 2013 |
Van Poppel H, Smith M, Borre M, Rathenborg P, Werbrouck P, Heidenreich A, Iversen P, Baskin-Bey E, Perabo F, Phung D, Tombal B. P061 Efficacy and safety of enzalutamide monotherapy in hormone-naive prostate cancer (HNPC) European Urology Supplements. 12: 152. DOI: 10.1016/S1569-9056(13)62386-6 |
0.306 |
|
| 2013 |
Tombal B, Borre M, Rathenborg P, Werbrouck P, Heidenreich A, Iversen P, Baskin-Bey E, Perabo F, Phung D, Smith M. 674 Enzalutamide monotherapy: Results from a phase 2 study in hormone naive prostate cancer patients European Urology Supplements. 12: e674-e675. DOI: 10.1016/S1569-9056(13)61156-2 |
0.337 |
|
| 2013 |
Miller K, Smith M, Dearnaley D, Dogliotti L, Egerdie B, Fizazi K, Kueppers F, Montes De Oca L, Morote J, Pavlik I, Sieber P, Tammela T, Van Poppel H, Wirth M, Wong S, et al. 108 Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) ≤6 months European Urology Supplements. 12: e108-e109. DOI: 10.1016/S1569-9056(13)60600-4 |
0.35 |
|
| 2013 |
Patrick D, Smith M, Cleeland C, Fallowfield L, Tombal B, Oudard S, Shore N, Saad F, Marx G, Coleman R, Gómez-Veiga F, Damião R, Zhou Y, Arellano J, Braun A, et al. 99 The impact of bone metastases on pain: Results from a phase III denosumab study in men with nonmetastatic castration-resistant prostate cancer European Urology Supplements. 12: e99-e100. DOI: 10.1016/S1569-9056(13)60591-6 |
0.307 |
|
| 2013 |
Van Poppel H, Rathkopf D, Smith M, De Bono J, Logothetis C, Shore N, De Souza P, Fizazi K, Mulders P, Mainwaring P, Hainsworth J, Beer T, North S, Fradet Y, Griffin T, et al. 97 Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy European Urology Supplements. 12: e97-e98. DOI: 10.1016/S1569-9056(13)60589-8 |
0.328 |
|
| 2013 |
Shore N, Basch E, Ryan CJ, Mulders P, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, et al. 784 THE IMPACT OF ABIRATERONE ACETATE THERAPY ON PATIENT-REPORTED PAIN AND FUNCTIONAL STATUS IN CHEMOTHERAPY-NAÏVE PATIENTS WITH PROGRESSIVE, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER - RESULTS FROM AN UPDATED ANALYSIS Journal of Urology. 189. DOI: 10.1016/J.JURO.2013.02.348 |
0.306 |
|
| 2012 |
Smith MR, Saad F, Shore ND, Oudard S, Miller K, Tombal B, Sieber P, Fizazi K, Van Veldhuizen PJ, Damião R, Marx GM, Morote J, Feng A, Dansey R, Goessl CD. Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 6. PMID 27968276 DOI: 10.1200/jco.2012.30.5_suppl.6 |
0.306 |
|
| 2012 |
Efstathiou JA, Paulus R, Smith MR, Jones CU, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU. Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 18. PMID 27967830 DOI: 10.1200/jco.2012.30.5_suppl.18 |
0.342 |
|
| 2012 |
Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discovery. 2: 995-1003. PMID 23093251 DOI: 10.1158/2159-8290.Cd-12-0222 |
0.316 |
|
| 2012 |
Morgans AK, Smith MR. Bone-targeted agents: preventing skeletal complications in prostate cancer. The Urologic Clinics of North America. 39: 533-46. PMID 23084529 DOI: 10.1016/j.ucl.2012.07.009 |
0.303 |
|
| 2012 |
Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 1670-5. PMID 22984218 DOI: 10.2967/jnumed.112.105007 |
0.303 |
|
| 2012 |
Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, Leder BZ, Goessl C. Sarcopenia during androgen-deprivation therapy for prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3271-6. PMID 22649143 DOI: 10.1200/Jco.2011.38.8850 |
0.311 |
|
| 2012 |
Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3677-85. PMID 22589396 DOI: 10.1158/1078-0432.CCR-11-3209 |
0.301 |
|
| 2012 |
Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee KA, Coleman RE, Smith MR. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. The Oncologist. 17: 645-52. PMID 22523198 DOI: 10.1634/Theoncologist.2011-0448 |
0.332 |
|
| 2012 |
Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. European Urology. 61: 1119-28. PMID 22336376 DOI: 10.1016/j.eururo.2012.01.045 |
0.329 |
|
| 2012 |
Morgans AK, Hancock ML, Barnette KG, Steiner MS, Morton RA, Smith MR. Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. The Journal of Urology. 187: 889-93. PMID 22245322 DOI: 10.1016/j.juro.2011.10.136 |
0.302 |
|
| 2012 |
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (London, England). 379: 39-46. PMID 22093187 DOI: 10.1016/S0140-6736(11)61226-9 |
0.318 |
|
| 2012 |
Sonpavde G, Pond G, Armstrong A, Galsky M, Wood B, Wang S, Paolini J, Lechuga M, Smith M, Michaelson M. Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer Annals of Oncology. 23: ix297-ix298. DOI: 10.1016/s0923-7534(20)33529-8 |
0.353 |
|
| 2012 |
de Bono J, Smith M, Rathkopf D, Corn P, Mukherji D, Harzstark A, Sartor O, Smith D, Tunariu N, Sweeney C. Cabozantinib (XL184) At 40 Mg in Patients with Metastatic Castration Resistant Prostate Cancer (MCRPC): Results of a Phase 2 Non-Randomized Expansion Cohort (NRE) Annals of Oncology. 23: ix296. DOI: 10.1016/s0923-7534(20)33492-x |
0.325 |
|
| 2012 |
Smith M, Antonarakis E, Ryan C, Berry W, Shore N, Liu G, Alumkal J, Higano C, Chow-Maneval E, Rathkopf D. ARN-509 in Men with High Risk Non-Metastatic Castration-Resistant Prostate Cancer Annals of Oncology. 23: ix303. DOI: 10.1016/s0923-7534(20)33478-5 |
0.336 |
|
| 2012 |
Basch E, Ryan C, Kheoh T, Fizazi K, Logothetis C, Rathkopf D, Smith M, Mainwaring P, Hao Y, Griffin T, Li S, Meyers M, Molina A, Cleeland C. The Impact of Abiraterone Acetate (AA) Therapy on Patient-Reported Pain and Functional Status in Chemotherapy-Naive Patients with Progressive, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Annals of Oncology. 23: ix295. DOI: 10.1016/s0923-7534(20)33470-0 |
0.306 |
|
| 2012 |
Feldman A, Banyard J, Fergus M, Jedrychowski M, Huttlin E, Gygi S, Smith M, Zettrer B. 2240 DISCOVERY AND ANALYSIS OF PROSTATE CANCER BIOMARKERS IN A STANDARD NON-POST-DRE VOIDED URINE SPECIMEN Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.2416 |
0.335 |
|
| 2012 |
Hu J, Williams S, O'Malley A, Smith M, Nguyen P, Keating N. 170 Androgen Deprivation Therapy For Non-Metastatic Prostate Cancer Is Associated With An Increased Risk Of Peripheral Arterial Disease And Venous Thromboembolism The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.221 |
0.315 |
|
| 2012 |
Preston M, Carrasquillo R, Coen J, Zietman A, Smith M, Wu C, McDougal WS, Feldman A. 1822 NEED FOR INTERVENTION AND SURVIVAL IN A COHORT OF PATIENTS ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER Journal of Urology. 187. DOI: 10.1016/J.JURO.2012.02.1888 |
0.303 |
|
| 2012 |
Carrasquillo R, Preston M, Coen J, Zietman A, Smith M, Wu C, McDougal WS, Feldman A. 1821 GLEASON UPGRADING AND INCREASED CANCER VOLUME ON REPEAT PROSTATE BIOPSY IN PATIENTS ON ACTIVE SURVEILLANCE Journal of Urology. 187. DOI: 10.1016/J.JURO.2012.02.1887 |
0.338 |
|
| 2012 |
Keating NL, Smith MR, Hu JC. Reply from Authors re: Ramdev Konijeti, Adam S. Kibel. Androgen Deprivation Therapy for Localized and Nonmetastatic Prostate Cancer: Too Much of a Good Thing? Eur Urol 2012;61:1129–30 European Urology. 61: 1131. DOI: 10.1016/J.EURURO.2012.03.044 |
0.334 |
|
| 2011 |
Smith DC, Smith MR, Small EJ, Sweeney C, Kurzrock R, Gordon MS, Vogelzang NJ, Scheffold C, Ballinger MD, Hussain M. Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 127. PMID 27968542 DOI: 10.1200/Jco.2011.29.7_Suppl.127 |
0.301 |
|
| 2011 |
Morgans AK, Smith MR. RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis. Journal of Osteoporosis. 2011: 941310. PMID 22013547 DOI: 10.4061/2011/941310 |
0.311 |
|
| 2011 |
Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3705-14. PMID 21860001 DOI: 10.1200/Jco.2010.34.4994 |
0.339 |
|
| 2011 |
Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4854-61. PMID 21632851 DOI: 10.1158/1078-0432.CCR-11-0815 |
0.368 |
|
| 2011 |
Smith MR. Effective treatment for early-stage prostate cancer - Possible, necessary, or both? New England Journal of Medicine. 364: 1770-1772. PMID 21542749 DOI: 10.1056/NEJMe1100787 |
0.303 |
|
| 2011 |
Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 117: 2077-85. PMID 21523719 DOI: 10.1002/Cncr.25762 |
0.318 |
|
| 2011 |
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (London, England). 377: 813-22. PMID 21353695 DOI: 10.1016/S0140-6736(10)62344-6 |
0.347 |
|
| 2011 |
Hatoum HT, Lin SJ, Guo A, Lipton A, Smith MR. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Current Medical Research and Opinion. 27: 55-62. PMID 21083514 DOI: 10.1185/03007995.2010.535511 |
0.344 |
|
| 2011 |
Kim HS, Moreira DM, Smith MR, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Bju International. 107: 924-8. PMID 20860651 DOI: 10.1111/j.1464-410X.2010.09679.x |
0.326 |
|
| 2011 |
Coen JJ, Feldman AS, Smith MR, Zietman AL. Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? Bju International. 107: 1582-6. PMID 20860650 DOI: 10.1111/j.1464-410X.2010.09652.x |
0.307 |
|
| 2011 |
Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone. 48: 88-95. PMID 20621630 DOI: 10.1016/J.Bone.2010.05.038 |
0.354 |
|
| 2011 |
Borkowski T, Smith M, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela T, Egerdie B, Van PH, Chin J, et al. C176 Prolonged Bone Metastasis-Free Survival In Men With Castrate-Resistant Prostate Cancer Receiving Denosumab: Results From A Phase 3, Randomised, Double-Blind Trial European Urology Supplements. 10: 656. DOI: 10.1016/S1569-9056(11)61756-9 |
0.324 |
|
| 2011 |
Oudard S, Smith M, Karsh L, Egerdie B, Van Veldhuizen P, Gómez-Veiga F, Dearnaley D, Ye Z, Dansey R, Goessl C. 7003 ORAL Denosumab and Bone Metastasis-free Survival in Men With Castrate-resistant Prostate Cancer – Subgroup Analyses From an International, Double-blind, Randomized, Phase 3 Trial European Journal of Cancer. 47: S484-S485. DOI: 10.1016/S0959-8049(11)71954-2 |
0.325 |
|
| 2011 |
Miller K, Fizazi K, Smith M, Moroto JP, Klotz L, Brown J, Tammela TL, Shore N, Ke C, Chung K, Goessl C. 648 BENEFIT OF DENOSUMAB THERAPY IN PATIENTS WITH BONE METASTASES FROM CASTRATE RESISTANT PROSTATE CANCER: A NUMBER-NEEDED-TO-TREAT (NNT) ANALYSIS Journal of Urology. 185. DOI: 10.1016/j.juro.2011.02.1550 |
0.346 |
|
| 2011 |
Efstathiou J, Paulus R, Smith M, Jones C, Leibenhaut M, Husain S, Rotman M, Souhami L, Sandler H, Shipley W. Cardiovascular Mortality following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08 International Journal of Radiation Oncology*Biology*Physics. 81: S41. DOI: 10.1016/J.IJROBP.2011.06.084 |
0.314 |
|
| 2011 |
Brown* J, Carducci M, Fizazi K, Smith M, Damião R, Karsh L, Milecki P, Wang H, Dansey R, Goessl C. Denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer: Results from a phase 3 randomized trial Bone. 48: S16. DOI: 10.1016/J.BONE.2010.10.042 |
0.318 |
|
| 2010 |
Lee RJ, Saylor PJ, Smith MR. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clinical Genitourinary Cancer. 8: 29-36. PMID 21208853 DOI: 10.3816/Cgc.2010.N.005 |
0.359 |
|
| 2010 |
Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. The Journal of Urology. 184: 1316-21. PMID 20723926 DOI: 10.1016/j.juro.2010.06.022 |
0.302 |
|
| 2010 |
Faris JE, Smith MR. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Current Opinion in Endocrinology, Diabetes, and Obesity. 17: 240-6. PMID 20404727 DOI: 10.1097/MED.0b013e3283391fd1 |
0.329 |
|
| 2010 |
Katz MS, Efstathiou JA, D’Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. Bjui. 105: 1417-1422. PMID 20346051 DOI: 10.1111/J.1464-410X.2010.09290.X |
0.306 |
|
| 2010 |
Efstathiou JA, Shipley WU, Zietman AL, Smith MR. Hormonal therapies: ADT for prostate cancer: true love or heartbreak? Nature Reviews. Clinical Oncology. 7: 130-2. PMID 20190794 DOI: 10.1038/nrclinonc.2010.12 |
0.345 |
|
| 2010 |
Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1481-8. PMID 20159824 DOI: 10.1200/JCO.2009.24.1281 |
0.351 |
|
| 2010 |
Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1496-501. PMID 20159814 DOI: 10.1200/Jco.2009.25.9259 |
0.35 |
|
| 2010 |
Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 8: 211-23. PMID 20141678 DOI: 10.6004/JNCCN.2010.0014 |
0.333 |
|
| 2010 |
Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 121: 833-40. PMID 20124128 DOI: 10.1161/Circulationaha.109.192695 |
0.366 |
|
| 2010 |
Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. Journal of General Internal Medicine. S389-94. PMID 19838837 DOI: 10.1007/s11606-009-0968-y |
0.342 |
|
| 2010 |
Ryan CJ, Smith MR, Logothetis C, Koepfgen K, Taplin M, Harzstark AL, Kantoff P, Kheoh TS, Molina A, Small EJ. Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred). Journal of Clinical Oncology. 28: 4671-4671. DOI: 10.1200/JCO.2010.28.15_SUPPL.4671 |
0.319 |
|
| 2010 |
Smith MR, Cook RJ, Nelson JB. Natural history of castration-resistant nonmetastatic prostate cancer: Secondary analyses of a multicenter randomized controlled trial. Journal of Clinical Oncology. 28: 4653-4653. DOI: 10.1200/Jco.2010.28.15_Suppl.4653 |
0.354 |
|
| 2010 |
Smith MR, Saad F, Egerdie B, Sieber P, Tammela TL, Kupic A, Ke C, Leder BZ, Goessl C. 132 SARCOPENIA IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY (ADT) FOR PROSTATE CANCER: A PROSPECTIVE 3-YEAR STUDY Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.183 |
0.359 |
|
| 2010 |
Smith M. Denosumab to Prevent Disease and Treatment-Related Skeletal Complications in Men with Prostate Cancer: Emerging Evidence Bone. 46: S17-S18. DOI: 10.1016/J.BONE.2010.01.029 |
0.331 |
|
| 2009 |
Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. Journal of the National Cancer Institute. 102: 39-46. PMID 19996060 DOI: 10.1093/jnci/djp404 |
0.318 |
|
| 2009 |
Saylor PJ, Smith MR. Prostate cancer: How can we improve the health of men who receive ADT? Nature Reviews Urology. 6: 529-531. PMID 19806171 DOI: 10.1038/nrurol.2009.195 |
0.332 |
|
| 2009 |
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 92-9. PMID 19047297 DOI: 10.1200/JCO.2007.12.3752 |
0.326 |
|
| 2009 |
Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE. Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks European Urology. 55: 62-75. PMID 18945543 DOI: 10.1016/j.eururo.2008.10.008 |
0.35 |
|
| 2009 |
Smith M, Egerdie B, Hernández TN, Feldman R, Tammela T, Saad F, Urban M, Szwedowski M, Ke C, Kupic A, Leder B, Goessl C. 846 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF DENOSUMAB IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR NON-METASTATIC PROSTATE CANCER European Urology Supplements. 8: 332. DOI: 10.1016/S1569-9056(09)60834-4 |
0.334 |
|
| 2009 |
Smith M, Egerdie B, Sieber P, Tammela T, Saad F, Ke C, Leder B, Dansey R, Goessl C. 7005 Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer European Journal of Cancer Supplements. 7: 407. DOI: 10.1016/S1359-6349(09)71383-7 |
0.327 |
|
| 2009 |
Egerdie B, Smith MR, Tammela TLj, Saad F, Ke C, Goessl C, Dansey R. A RESPONDER ANALYSIS OF THE EFFECTS OF DENOSUMAB ON BONE MINERAL DENSITY IN MEN WITH PROSTATE CANCER RECEIVING ANDROGEN DEPRIVATION THERAPY The Journal of Urology. 181: 611. DOI: 10.1016/S0022-5347(09)61717-1 |
0.343 |
|
| 2009 |
Smith MR, Egerdie B, Szwedowski M, Ke C, Leder B, Goessl C. EFFECTS OF TWICE-YEARLY SUBCUTANEOUS DENOSUMAB ON BONE MINERAL DENSITY IN MEN RECEIVING ANDROGEN-DEPRIVATION THERAPY FOR NON-METASTATIC PROSTATE CANCER Journal of Urology. 181: 229-229. DOI: 10.1016/S0022-5347(09)60652-2 |
0.346 |
|
| 2008 |
Smith MR. Osteoporosis in men with prostate cancer: Now for the fracture data Journal of Clinical Oncology. 26: 4371-4372. PMID 18802147 DOI: 10.1200/JCO.2008.17.9507 |
0.3 |
|
| 2008 |
Smith MR. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors Current Urology Reports. 9: 197-202. PMID 18765113 DOI: 10.1007/s11934-008-0035-y |
0.323 |
|
| 2008 |
Smith MR. Osteoclast targeted therapy for prostate cancer: Bisphosphonates and beyond Urologic Oncology: Seminars and Original Investigations. 26: 420-425. PMID 18593621 DOI: 10.1016/j.urolonc.2007.11.004 |
0.324 |
|
| 2008 |
Smith MR. Rapid testosterone cycling and chemotherapy for prostate cancer: A way forward or return to the past? Journal of Clinical Oncology. 26: 2932-2933. PMID 18565878 DOI: 10.1200/JCO.2008.16.0788 |
0.348 |
|
| 2008 |
Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. Ca: a Cancer Journal For Clinicians. 58: 196-213. PMID 18502900 DOI: 10.3322/CA.2008.0002 |
0.362 |
|
| 2008 |
Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. Bju International. 101: 1084-9. PMID 18399827 DOI: 10.1111/J.1464-410X.2008.07509.X |
0.336 |
|
| 2008 |
Smith MR, Malkowicz SB, Chu F, Forrest J, Sieber P, Barnette KG, Rodriquez D, Steiner MS. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1824-9. PMID 18398147 DOI: 10.1200/JCO.2007.13.5517 |
0.304 |
|
| 2008 |
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. European Urology. 54: 816-23. PMID 18243498 DOI: 10.1016/j.eururo.2008.01.021 |
0.326 |
|
| 2008 |
Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR. Use of androgen deprivation therapy for metastatic prostate cancer in older men. Bju International. 101: 1077-83. PMID 18190632 DOI: 10.1111/j.1464-410X.2007.07405.x |
0.369 |
|
| 2008 |
Lee RJ, Smith MR. Osteoclast-targeted therapy for metastatic prostate cancer Therapy. 5: 63-72. DOI: 10.2217/14750708.5.1.63 |
0.328 |
|
| 2008 |
Smith MR. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors Current Prostate Reports. 6: 149-154. DOI: 10.1007/s11918-008-0023-1 |
0.302 |
|
| 2007 |
Smith MR. Androgen deprivation therapy for prostate cancer: New concepts and concerns Current Opinion in Endocrinology, Diabetes and Obesity. 14: 247-254. PMID 17940447 DOI: 10.1097/MED.0b013e32814db88c |
0.32 |
|
| 2007 |
Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F. Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer Urology. 70: 315-319. PMID 17826496 DOI: 10.1016/J.Urology.2007.03.071 |
0.34 |
|
| 2007 |
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Body mass index and mortality in men treated for locally advanced prostate cancer: An analysis of RTOG 85–31 Journal of Clinical Oncology. 25: 5128-5128. DOI: 10.1200/jco.2007.25.18_suppl.5128 |
0.339 |
|
| 2007 |
Malkowicz SB, Chu F, Forrest J, Smith MR, Price D, Sieber P, Barnette KG, Rodriguez D, Steiner MS. Prevalence of osteoporosis and osteopenia during androgen deprivation (ADT) for prostate cancer: Baseline data from a large randomized controlled trial Journal of Clinical Oncology. 25: 5116-5116. DOI: 10.1200/JCO.2007.25.18_SUPPL.5116 |
0.303 |
|
| 2007 |
Smith MR, Chu F, Forrest J, Malkowicz SB, Price D, Sieber P, Barnette K, Rodriguez D, Steiner M. 1015: Phase III Interim Analysis Demonstrates Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Journal of Urology. 177: 335-335. DOI: 10.1016/S0022-5347(18)31243-6 |
0.341 |
|
| 2007 |
Efstathiou J, Bae K, Shipley W, Hanks G, Pilepich M, Sandler H, Smith M. Cardiovascular Mortality Following Androgen Deprivation Therapy in Men With Locally Advanced Prostate Cancer: An Analysis of RTOG 85-31 International Journal of Radiation Oncology*Biology*Physics. 69: S170-S171. DOI: 10.1016/J.IJROBP.2007.07.309 |
0.338 |
|
| 2006 |
Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 107: 530-5. PMID 16804927 DOI: 10.1002/cncr.22043 |
0.304 |
|
| 2006 |
Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2723-8. PMID 16782912 DOI: 10.1200/JCO.2005.03.7804 |
0.356 |
|
| 2006 |
Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clinical Cancer Research. 12: 3361-3367. PMID 16740758 DOI: 10.1158/1078-0432.Ccr-06-0269 |
0.343 |
|
| 2006 |
Smith MR. Markers of bone metabolism in prostate cancer Cancer Treatment Reviews. 32: 23-26. PMID 16680835 DOI: 10.1016/S0305-7372(06)80006-X |
0.323 |
|
| 2006 |
Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA. Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opinion On Investigational Drugs. 15: 293-305. PMID 16503765 DOI: 10.1517/13543784.15.3.293 |
0.371 |
|
| 2006 |
Smith MR. Therapy Insight: osteoporosis during hormone therapy for prostate cancer. Nature Clinical Practice. Urology. 2: 608-15; quiz 628. PMID 16474548 DOI: 10.1038/ncpuro0326 |
0.312 |
|
| 2006 |
Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. The Journal of Clinical Endocrinology and Metabolism. 91: 1305-8. PMID 16434464 DOI: 10.1210/JC.2005-2507 |
0.307 |
|
| 2005 |
Smith MR, Kabbinavar F, Saad F, Hussain A, Hei YJ, Small E, Cook R, Higano C. Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4514. PMID 27946530 DOI: 10.1200/Jco.2005.23.16_Suppl.4514 |
0.368 |
|
| 2005 |
Duh MS, Smith MR, Boyce SP, Moyneur E, Raut MR, Brandman J, Sung JC. Risk factors for clinical fractures among men with non-metastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4560. PMID 27946395 DOI: 10.1200/jco.2005.23.16_suppl.4560 |
0.323 |
|
| 2005 |
Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7897-903. PMID 16258089 DOI: 10.1200/JCO.2004.00.6908 |
0.305 |
|
| 2005 |
Smith MR, Nelson JB. Future therapies in hormone-refractory prostate cancer. Urology. 65: 9-16; discussion 17. PMID 15885273 DOI: 10.1016/j.urology.2005.03.043 |
0.343 |
|
| 2005 |
Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2918-25. PMID 15860850 DOI: 10.1200/Jco.2005.01.529 |
0.561 |
|
| 2004 |
Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, et al. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. The Journal of Urology. 172: S3-5. PMID 15535434 DOI: 10.1097/01.ju.0000142276.19511.ac |
0.323 |
|
| 2004 |
Smith MR. Osteoclast-targeted therapy for prostate cancer Current Treatment Options in Oncology. 5: 367-375. PMID 15341675 DOI: 10.1007/S11864-004-0027-1 |
0.366 |
|
| 2004 |
Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3705-12. PMID 15289492 DOI: 10.1200/JCO.2004.10.195 |
0.355 |
|
| 2004 |
Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 101: 541-9. PMID 15274067 DOI: 10.1002/cncr.20388 |
0.322 |
|
| 2004 |
Michaelson MD, Marujo RM, Smith MR. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2705-8. PMID 15102674 DOI: 10.1158/1078-0432.CCR-03-0735 |
0.37 |
|
| 2004 |
Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 100: 892-9. PMID 14983482 DOI: 10.1002/cncr.20056 |
0.307 |
|
| 2004 |
Kazanis M, Smith MR. Treatment-Related Osteoporosis in Men With Prostate Cancer Clinical Reviews in Bone and Mineral Metabolism. 2: 115-122. DOI: 10.1385/BMM:2:2:115 |
0.344 |
|
| 2004 |
Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Smith MR, Kaufman DS, Kantoff PW. A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC) Journal of Clinical Oncology. 22: 4656-4656. DOI: 10.1200/jco.2004.22.90140.4656 |
0.339 |
|
| 2004 |
Smith MR, Lee WC, Krupsi T, Brandman J, Wang Q, Botteman M, Pashos C, Litwin M. Association between androgen deprivation therapy and fracture risk: A population-based cohort study in men with non-metastatic prostate cancer Journal of Clinical Oncology. 22: 4507-4507. DOI: 10.1200/JCO.2004.22.90140.4507 |
0.321 |
|
| 2004 |
Krupski TL, Smith MR, Lee WC, Pashas CL, Brandman J, Wang Q, Botteman MF, Litwin MS. 438: Fracture Risk in Men with Prostate Cancer on Androgen Deprivation Therapy Journal of Urology. 171: 116-116. DOI: 10.1016/S0022-5347(18)37700-0 |
0.324 |
|
| 2003 |
Smith MR, Kantoff PW, Carroll PR, Benaron DA, Sellers WR, Higano CS. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer Journal of Urology. 170: S55-S58. PMID 14610411 DOI: 10.1097/01.ju.0000095102.34708.bc |
0.361 |
|
| 2003 |
Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, et al. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. The Journal of Urology. 170: S3-5. PMID 14610403 DOI: 10.1097/01.Ju.0000095101.18470.A0 |
0.323 |
|
| 2003 |
Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 4277-84. PMID 14581438 DOI: 10.1200/JCO.2003.05.147 |
0.322 |
|
| 2003 |
Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology. 62: 99-104. PMID 12837431 DOI: 10.1016/S0090-4295(03)00145-6 |
0.366 |
|
| 2003 |
Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. The Journal of Urology. 169: 2008-12. PMID 12771706 DOI: 10.1097/01.ju.0000063820.94994.95 |
0.331 |
|
| 2003 |
Michaelson MD, Smith MR. The role of bisphosphonates in the management of metastatic prostate cancer. Current Oncology Reports. 5: 245-9. PMID 12667423 DOI: 10.1007/S11912-003-0117-4 |
0.382 |
|
| 2003 |
Pirl WF, Siegel GI, Goode MJ, Smith MR. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psycho-Oncology. 11: 518-23. PMID 12476433 DOI: 10.1002/PON.592 |
0.331 |
|
| 2002 |
Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, ... Smith MR, et al. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 60: 1-6. PMID 12231036 |
0.347 |
|
| 1999 |
Smith MR, Kantoff PW, Oh W, Elson G, Manola J, McMullin M, Jacobsen J, Brufsky A, Kaufman D. Phase II Trial of the Antiestrogen Toremifene for Androgen-Independent Prostate Cancer The Prostate Journal. 1: 185-189. DOI: 10.1046/J.1525-1411.1999.14003.X |
0.32 |
|
| Show low-probability matches. |